Pulmatrix, Inc. (PULM) News

Pulmatrix, Inc. (PULM): $2.13

0.07 (-3.18%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add PULM to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#104 of 386

in industry

Filter PULM News Items

PULM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PULM News From Around the Web

Below are the latest news stories about PULMATRIX INC that investors may wish to consider to help them evaluate PULM as an investment opportunity.

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2023 and provided a corporate update on its development programs.

Yahoo | November 9, 2023

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Eval

Yahoo | September 19, 2023

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology. PUR1900 is an orally inhaled dry powder formulation of the antifungal itraconazole, utilizing iSPERSE technology, being developed for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with asthma.

Yahoo | August 23, 2023

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2023 and provided a corporate update on its development programs.

Yahoo | August 10, 2023

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease, today announced the submission of an investigational new drug ("IND") application to the United States Food and Drug Administration ("FDA") for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE"), under development to treat acute migraine. The PUR3100 formulatio

Yahoo | July 11, 2023

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced it will present data at the American Headache Society 65th Annual Meeting, being held from June 15th through 18th both virtually and in-person at the J.W. Marriott in Austin, Texas.

Yahoo | June 15, 2023

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced that management will present at the annual Biotechnology Innovation Organization (BIO) International Convention, to be held in-person in Boston, MA, June 5 - 8, 2023. Presentation details are below. Pulmatrix management will also be available for one-on-one meeting

Yahoo | May 24, 2023

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced first quarter financial results for 2023 and provided a corporate update on its development programs.

Yahoo | May 12, 2023

Pulmatrix Supports World Asthma Day 2023

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced its support for World Asthma Day.

Yahoo | May 2, 2023

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.

Yahoo | March 30, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!